| Latest Biopure Class A News Headlines |
| Date | Time | Source | |
| 07/07/2008 | 7:49AM | PRNUS | Biopure Announces Meeting With FDA
CAMBRIDGE, Mass., July 7 /PRNewswire-FirstCall/ -- Biopure Corporation (NASDAQ:BPUR) announced today that it has had discussions with the Food and Drug Administration (FDA) on identifying an acceptable patient population for a new clinical trial of Hemopure(R) [hemoglobin glutamer - 250 (bovine)], or HBOC-201. Biopure... More...>> |
| 07/02/2008 | 4:18PM | PRNUS | Biopure Announces Private Equity Financing
CAMBRIDGE, Mass., July 2 /PRNewswire-FirstCall/ -- Biopure Corporation (NASDAQ:BPUR) announced today that it has signed an agreement with purchasers for a private placement of its common stock and warrants for up to $2.3 million in tranches, assuming no exercise of the warrants. The company intends to use the net proceeds... More...>> |
| 06/18/2008 | 4:15PM | PRNUS | U.S. Navy Submits Protocol for Field Trauma Trial of Hemopure(R)
CAMBRIDGE, Mass., June 18 /PRNewswire-FirstCall/ -- Biopure Corporation (NASDAQ:BPUR) announced today that the U.S. Naval Medical Research Center (NMRC) has submitted a new protocol for review by the Food and Drug Administration (FDA) for a Phase 2 clinical trial of Hemopure(R) [hemoglobin glutamer - 250 (bovine)]... More...>> |
| 06/12/2008 | 4:30PM | PRNUS | Biopure Granted Additional 180 Day Compliance Period by NASDAQ
CAMBRIDGE, Mass., June 12 /PRNewswire-FirstCall/ -- Biopure Corporation (NASDAQ:BPUR) announced today that The NASDAQ Stock Market has granted the Company an additional 180 days, or until December 8, 2008, to regain compliance with Marketplace Rule 4310(c)(4) requiring a minimum bid price of $1.00 for continued listing... More...>> |
| 06/10/2008 | 4:35PM | PRNUS | Biopure Phase III Orthopedic Trial Results Published in Journal of Trauma
CAMBRIDGE, Mass., June 10 /PRNewswire-FirstCall/ -- Biopure Corporation (NASDAQ:BPUR) today announced that the results from its Phase III orthopedic trial (HEM-115) have been published in the June 2008 issue of the Journal of Trauma. This paper is entitled "HBOC-201 as an Alternative to Blood Transfusion: Efficacy... More...>> |
| 06/09/2008 | 8:08AM | PRNUS | Biopure Responds to JAMA and Meta-Analysis
CAMBRIDGE, Mass., June 9 /PRNewswire-FirstCall/ -- Biopure Corporation (NASDAQ:BPUR) today announced that it has sent an open letter to the editors of the Journal of the American Medical Association (JAMA). The letter asks for a retraction of the meta-analysis and the accompanying editorial that appeared on line on... More...>> |
| 06/05/2008 | 10:24AM | PRNUS | Biopure Announces MHRA Meeting Update
CAMBRIDGE, Mass., June 5 /PRNewswire-FirstCall/ -- Biopure Corporation (NASDAQ:BPUR) announced today an update regarding a meeting with the Medicines and Healthcare products Regulatory Agency (MHRA) addressing the Company's pending application for marketing authorization for Hemopure(R) [hemoglobin glutamer - 250 (bovine)].
The... More...>> |
| 05/21/2008 | 5:30PM | PRNUS | Biopure Announces 2008 Second Quarter Financial Results
CAMBRIDGE, Mass., May 21 /PRNewswire-FirstCall/ -- Biopure Corporation (NASDAQ:BPUR) today announced its financial results for the second fiscal quarter ended April 30, 2008. For the quarter, the company reported a net loss of $5.0 million, or $0.14 per common share, compared with a net loss of $6.2 million, or $0.40... More...>> |
| 05/19/2008 | 8:30AM | PRNUS | Biopure Wins European Patent Challenge
CAMBRIDGE, Mass., May 19 /PRNewswire-FirstCall/ -- Biopure Corporation (NASDAQ:BPUR) announced today that it has successfully defended a challenge at the European Patent Office (EPO) to its European Patent entitled, "A Method for Chromatographic Removal of Prions." This European Patent covers Biopure's innovative purification... More...>> |
| 05/14/2008 | 4:35PM | PRNUS | Biopure Announces Publication of Phase II Proof-of-Concept Coronary Trial
CAMBRIDGE, Mass., May 14 /PRNewswire-FirstCall/ -- Biopure Corporation (NASDAQ:BPUR) today announced that the results from its Phase II coronary revascularization trial have been published in the peer-reviewed EuroIntervention Journal. The paper is entitled "Proof-of-concept trial to evaluate haemoglobin based oxygen... More...>> |
| 05/14/2008 | 8:30AM | PRNUS | Biopure Appoints Dechra Exclusive U.S. Distributor of Oxyglobin
CAMBRIDGE, Mass., May 14 /PRNewswire-FirstCall/ -- Biopure Corporation (NASDAQ:BPUR) today announced it has appointed Dechra Veterinary Products as exclusive distributor for Oxyglobin(R) solution [hemoglobin glutamer-200 (bovine)] or HBOC-301, in the U.S. Oxyglobin is the only FDA-approved treatment for canine anemia... More...>> |
| 05/08/2008 | 8:30AM | PRNUS | U.S. Navy Receives Funding for Further Development of Hemopure(R)
CAMBRIDGE, Mass., May 8 /PRNewswire-FirstCall/ -- Biopure Corporation (NASDAQ:BPUR) announced today that the Naval Medical Research Center (NMRC) has received new funding of approximately $3.4 million for the development of Hemopure(R) (HBOC-201). These funds are being granted through the Department of Defense for... More...>> |
| 05/07/2008 | 2:46PM | PRNUS | Biopure Reaffirms Strategy Following Recent NIH/FDA Workshop
Panel on Hemoglobin-Based Oxygen Carriers Indicates Support for Continued Investigational Use Where Blood Is Not an Option
CAMBRIDGE, Mass., May 7 /PRNewswire-FirstCall/ -- Biopure Corporation (NASDAQ:BPUR) announced today that the Company's strategy to pursue indications for its product Hemopure(R) [hemoglobin glutamer-250... More...>> |
| 05/07/2008 | 9:49AM | PRNUS | Biopure Reaffirms Strategy Following Recent NIH/FDA Workshop
Panel on Hemoglobin-Based Oxygen Carriers Indicates Support for Continued Investigational Use Where Blood Is Not an Option
CAMBRIDGE, Mass., May 7 /PRNewswire-FirstCall/ -- Biopure Corporation (NASDAQ:BPUR) announced today that the Company's strategy to pursue indications for its product Hemopure(R) [hemoglobin glutamer-250... More...>> |
| 05/02/2008 | 2:11PM | PRNUS | Biopure Announces Date to Meet with UK's Medicines and Healthcare Products Agency
CAMBRIDGE, Mass., May 2 /PRNewswire-FirstCall/ -- Biopure Corporation (NASDAQ:BPUR) today announced that a meeting with the United Kingdom's Medicines and Healthcare Products Regulatory Agency (MHRA) is scheduled for May 29, 2008 in the UK.
The purpose of the meeting is to clarify the issues outlined in a letter Biopure... More...>> |
| 04/11/2008 | 8:00AM | PRNUS | Biopure Operations Compliant With U.K. Manufacturing Guidelines
CAMBRIDGE, Mass., April 11 /PRNewswire-FirstCall/ -- Biopure Corporation (NASDAQ:BPUR) announced today that the United Kingdom's Medicines and Healthcare products Regulatory Agency (MHRA) has found the company's Pennsylvania manufacturing facility to be in general compliance with the principles and guidelines of good... More...>> |
| 04/10/2008 | 8:00AM | PRNUS | Biopure Appoints New Independent Auditor
CAMBRIDGE, Mass., April 10 /PRNewswire-FirstCall/ -- Biopure Corporation (NASDAQ:BPUR) announced today that it has engaged Vitale, Caturano & Company, Ltd as its independent auditor.
The audit committee of Biopure's board of directors made its selection after a review of audit firms that had expertise with public clients... More...>> |
| 04/07/2008 | 7:00AM | PRNUS | Biopure Receives Comment Letter From U.K. Regulatory Body on Marketing Application for Hemopure(R)
CAMBRIDGE, Mass., April 7, 2008 /PRNewswire-FirstCall/ -- Biopure Corporation (NASDAQ:BPUR) announced today that it has received a comment letter from the United Kingdom's Commission on Human Medicines addressing the company's application for marketing authorization for Hemopure(R) [hemoglobin glutamer - 250 (bovine)]... More...>> |
| 03/19/2008 | 4:50PM | PRNUS | Biopure Completes U.K. Regulatory Agency Inspection
CAMBRIDGE, Mass., March 19 /PRNewswire-FirstCall/ -- Biopure Corporation (NASDAQ:BPUR) announced today that the United Kingdom's Medicines and Healthcare products Regulatory Agency (MHRA) has completed its inspection of the company's Pennsylvania manufacturing facility. The inspection report contained no "Critical... More...>> |
| 02/26/2008 | 9:46AM | PRNUS | Biopure Announces 2008 First Quarter Financial Results
CAMBRIDGE, Mass., Feb. 21 /PRNewswire-FirstCall/ -- Biopure Corporation (NASDAQ:BPUR) today announced its financial results for the first fiscal quarter ended January 31, 2008. For the quarter, the company reported a net loss of $5.8 million, or $0.17 per common share, compared with a net loss of $6.9 million, or $0.53... More...>> |